GlassScriptPhysician profile
David K Tran
NPI 1811459928
$6,395.73
in general payments reported to CMS, 2019-2025
24 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.86 · 2022: $171 · 2023: $1,751 · 2024: $2,502 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,013.31 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $901.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $878.18 | 2023-2025 | Vraylar, Ubrelvy, Synthroid |
| Phathom Pharmaceuticals, INC. | $438.57 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $387.14 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $321.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $302.23 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $273.29 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $263.72 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.44 | 2023-2024 | |
| Dynavax Technologies Corporation | $237.16 | 2023-2025 | Heplisav-B |
| Axogen | $229.37 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Cap |
| Boston Scientific Corporation | $213.60 | 2022-2025 | Watchman Access System, Intracept |
| Idorsia Pharmaceuticals US INC | $164.93 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $144.95 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $101.34 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $89.52 | 2023-2025 | Dexcom G6 Transmitter |
| Kerecis Limited | $48.26 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Polynovo North America LLC | $32.30 | 2024 | Novosorb Btm |
| Dompe US, INC. | $28.38 | 2025 | Oxervate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.13 | 2025 | Xifaxan |
| Lundbeck LLC | $20.28 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2025 | Jardiance |
| Shield Therapeutics INC | $15.15 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.